5-Aminosalicylic acid-d3 is the deuterium labeled 5-Aminosalicylic Acid. 5-Aminosalicylic acid (Mesalamine) acts as a specific PPARγ agonist and also inhibits p21-activated kinase 1 (PAK1) and NF-κB[1][2][3][4].
AAPH (2,2'-Azodiisobutyramidine dihydrochloride) has an effect of radical generation. AAPH induces oxidative stress and erythrocyte hemolysis[1].
The compound is an a1/a3 adenosine receptor antagonist, which helps to treat (neurological) inflammatory diseases.
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction[1][2]. Ablukast is LTD4 receptor antagonist[3].
Polygalasaponin F, an oleanane-type triterpenoid saponin extracted from Polygala japonica, decreases the release of the inflammatory cytokine tumor necrosis factor a (TNFa). Polygalasaponin F reduces neuroinflammatory cytokine secretion through the regulation of the TLR4-PI3K/AKT-NF-kB signaling pathway [1].
LY-311727 is a potent secretory non-pancreatic phospholipase A2 (sPLA2) inhibitor (IC50 <1 μM for group IIA sPLA2). sPLA2 is an important proinflammatory enzyme[1][2].
TRAF-STOP inhibitor 6877002, is a selective inhibitor of CD40-TRAF6 interaction, compound VII, shows inhibition of NF-κB activation in RAW cells, extracted from patent WO2014033122A1[1]. TRAF-STOP 6877002 prevents the progression of established atherosclerosis in mice, reduces leukocyte recruitment and reduces macrophage activation; reduces macrophage proliferation in atherosclerotic plaques[2].
Polygodial (Poligodial) is an antifungal potentiator[1]. Polygodial is a sesquiterpene with anti-hyperalgesic properties[2].
Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases[1][2].
Moracin O is a 2-arylbenzofuran isolated from the Mori Cortex Radicis. Moracin O exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1). Moracin O reduces oxygen-glucose deprivation (OGD)-induced reactive oxygen species (ROS) production. Moracin O has neuroprotective and anti-inflammatory effects[1][2][3].
SMS2-IN-1 is a highly selective sphingomyelin synthase 2 (SMS2) inhibitor with an IC50 of 6.5 nM.
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody targeting to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD)[1][2].
Resiquimod is a Toll-like receptor 7 and 8 (TLR7/TLR8) agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α.
PF-10040 is a quinoline derivative that can inhibit PAF-induced airway hyperresponsiveness. PF-10040 also shows protective effect in experimental NSAID-gastritis[1][2].
Sintilimab (IBI308) is a fully human IgG4 monoclonal antibody that binds to PD-1, thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2) and consequently helping to restore the endogenous antitumour T-cell response. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1].
Tectorigenin is a plant isoflavonoid originally isolated from the dried flower of Pueraria thomsonii Benth.
Hyponine E, a macrocyclic sesquiterpene pyridine alkaloid that could be isolated from from Tripterygium hypoglaucum, possesses anti-inflammatory effects[1][2].
Nedocromil suppresses the action or formation of multiple mediators, including histamine, leukotriene C4 (LTC4), and prostaglandin D2 (PGD2).
CYM 50769 is a non-peptidic selective antagonist of neuropeptides B and W receptor 1 (NPBWR1). CYM 50769 can attenuates the NPW-23-induced cell proliferation in ATDC5. CYM 50769 can be used for researching endochondral bone formation[1].
Oditrasertib is a RIPKl inhibitor with an IC50 value lower than 100 nM. Oditrasertib can be used for the research of Inflammation[1].
Cedelizumab (RWJ 49004) is a IgG4 monoclonal antibody targeting CD4. Cedelizumab has immunosuppressant properties[1].
Olutasidenib is a highly potent, selective inhibitor of mutant Isocitrate dehydrogenase (IDH)1 that could be used in the treatment of acute myeloid leukemia.
GW274150 (dihydrochloride) is a potent, selective, orally active and NADPH-dependent inhibitor of human inducible nitric oxide synthase (iNOS) (IC50=2.19 μM; Kd=40 nM) and rat iNOS (ED50=1.15 μM). GW274150 (dihydrochloride) displays less potency for both humans or rats endothelial NOS (eNOS) and neuronal NOS (nNOS). GW274150 (dihydrochloride) exerts a protective role in an acute model of lung injury inflammation[1][2][3].
LNP023 hydrochloride is an orally bioavailable, highly potent and highly selective factor B inhibitor. LNP023 shows direct, reversible, and high-affinity binding to human factor B with a KD of 7.9 nM. LNP023 inhibits factor B with an IC50 value of 10 nM[1][2].
ASK1-IN-5 (S-99) is an inhibitor of apoptosis signal-regulated kinase 1 (ASK1) and is useful in the study of autoimmune and neurodegenerative diseases[1].
Glucocorticoids receptor agonist 2 is a potent anti-inflammatory, arylpyrazole-based glucocorticoid receptor agonist that does not impair insulin secretion.
Phlorigidoside C, a natural iridoid glucoside, possesses anti-rheumatoid arthritis effect[1].
Se-DMC attenuates complete Freund’s adjuvant (CFA)-induced inflammatory response, nociception, and neurobehavioral deficits in mice.
Di-O-methyldemethoxycurcumin, a curcuminoid analog isolated from the medicinal plant Curcuma longa L., inhibits IL-6 production with an EC50 of 16.20 μg/mL. Anti-inflammatory and antioxidant properties[1].
MuRF1-IN-2 (Example 3) is a MuRF1 inhibitor. MuRF1-IN-2 can be used for research of muscle wasting conditions, of skeletal or cardial muscle atrophy[1].